We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

Intra-Cellular Therapies Inc (ITCI) stock saw a decline, ending the day at $126.2 which represents a decrease of $-0.06 or -0.05% from the prior close of $126.26. The stock opened at $126.65 and ...

"Berries offer an exceptional combination of nutrients and compounds that support longevity and healthy aging. They’re ...

High-speed internet is not a luxury—it is a lifeline for economic opportunity. More than $1.3 billion was invested in the BPO ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion to enhance its neuroscience drug portfolio.

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...